Industry
Jiangsu Rec-Biotechnology Co., Ltd.
Total Trials
5
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
Failure Rate
0.0%
0 terminated/withdrawn out of 5 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 2
2(40.0%)
Early Phase 1
1(20.0%)
Phase 1
1(20.0%)
Phase 3
1(20.0%)
5Total
Phase 2(2)
Early Phase 1(1)
Phase 1(1)
Phase 3(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (5)
Showing 5 of 5 trials
NCT05769049Phase 1Completed
The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)
Role: lead
NCT05398848Phase 3Completed
Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)
Role: lead
NCT05084989Phase 2Completed
Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)
Role: lead
NCT05323435Phase 2Completed
Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)
Role: lead
NCT04818801Early Phase 1Completed
Safety, Reactogenicity and Immunogenicity Study of ReCOV
Role: lead
All 5 trials loaded